Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
24.58
+4.12 (20.14%)
NYSE · Last Trade: Nov 5th, 11:40 AM EST
Detailed Quote
Previous Close
20.46
Open
23.06
Bid
24.58
Ask
24.59
Day's Range
22.70 - 24.60
52 Week Range
12.47 - 22.80
Volume
27,469,453
Market Cap
27.29B
PE Ratio (TTM)
-153.63
EPS (TTM)
-0.2
Dividend & Yield
N/A (N/A)
1 Month Average Volume
8,808,001
Chart
About Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Teva Pharmaceutical Industries is a global leader in the pharmaceutical industry, specializing in the development, production, and marketing of a wide range of generic and specialty medications. The company is committed to improving patient access to high-quality medicines and focuses on therapeutic areas such as central nervous system disorders, pain management, respiratory diseases, and more. With a robust portfolio that includes both branded and generic products, Teva leverages its extensive research capabilities to innovate and provide solutions that meet the evolving healthcare needs of patients and healthcare professionals around the world. Read More
In a period marked by cautious optimism and strategic pivots, several prominent companies across diverse sectors have recently defied broader economic uncertainties to achieve significant 52-week highs. As of late 2025, pharmaceutical giant Eli Lilly, defense and safety solutions provider Cadre Holdings, energy major BP, global food company Kellanova, and
PARSIPPANY, N.J. and TEL AVIV, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of ‘The Other TD,’ a disease education campaign leveraging the broad recognition of football touchdowns to raise awareness and understanding of a lesser-known TD – tardive dyskinesia. The goal of the campaign is to help undiagnosed Americans living with TD, and their care partners, recognize symptoms and take action by having conversations with their healthcare provider. Terrell Davis, known for his iconic initials, “TD,” and for scoring dozens of touchdowns in his career, is partnering with Teva to shine a light on ‘The Other TD’.
TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in November as follows:
TEL AVIV, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue® (trastuzumab), a biosimilar to Herceptin®, across a majority of European markets.
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has approved UZEDY® (risperidone) as a once-monthly extended-release injectable suspension as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder (BD-I) in adults. The approval is based on existing clinical data for UZEDY, coupled with Model-Informed Drug Development (MIDD) methodologies that leverage previous findings on the safety and efficacy of risperidone formulations already approved for BD-I.
Duquesne Family Office's billionaire boss bid adieu to Wall Street's hottest AI stocks in favor of another trillion-dollar company and a long-awaited turnaround story in the healthcare sector.
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on its website.
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday, November 5, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of data from a real-world survey of patients taking AUSTEDO XR® (deutetrabenazine) extended-release tablets. Patients taking AUSTEDO XR reported increased social and emotional well-being as a result of movement reduction, and high overall satisfaction with AUSTEDO XR. The data were presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025 in San Diego, California.
PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of 10 posters from its innovative schizophrenia medicines portfolio, including long-term safety data from the completed SOLARIS Phase 3 trial showing no incidence of post-injection delirium/sedation syndrome (PDSS) in study participants taking olanzapine LAI (TEV-'749), a once-monthly, long-acting injectable (LAI) subcutaneous formulation of olanzapine.1 New data evaluating UZEDY®, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, found that it was associated with a shorter length of hospitalization compared to a once-monthly intramuscular injection of Invega Sustenna®.1 No comparisons can be made regarding efficacy, safety, or any other clinical outcomes as this was not studied. The data were presented at the 2025 Psych Congress Annual Meeting, taking place from September 17–21, 2025, in San Diego, California.
TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California.
PARSIPPANY, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Teva’s investigational therapy emrusolmin (TEV-56286) for the treatment of Multiple System Atrophy (MSA). Emrusolmin is part of a strategic collaboration with MODAG GmbH, a privately held German biotech company, and is currently being evaluated in a Phase 2 trial to assess its efficacy and safety. The U.S. FDA granted Orphan Drug designation to emrusolmin for MSA in 2022.
TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in September as follows:
